Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study

Yıldırım, Bünyamin; GÜZEL, Tuncay; Arslan, Bayram; Kılıç, Raif; Argun, Lokman; ERTAŞ, Faruk; Yentür, Merve; İldırımlı, Kamran; DEMİR, Muhammed; özbek, mehmet; YILDIZ, Halil; Aktan, Adem; ARIK, BARAN

Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study

Tuncay Güzel, (Kardiyoloji Anabilim Dalı, Sağlık Bilim Üniversitesi, Gazi Yaşargil Eğitimi ve Araştırma Hastanesi, Diyarbakır, Türkiye)

Adem Aktan, (Kardiyoloji Anabilim Dalı, Mardin Eğitim ve Araştırma Hastanesi, Mardin, Türkiye)

Raif Kılıç, (Kardiyoloji Anabilim Dalı, Diyarlife Hastane, Diyarbakır, Türkiye)

Bayram Arslan, (Kardiyoloji Anabilim Dalı, Ergani Eyaleti Hastane, Diyarbakır, Türkiye)

Baran Arık, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Merve Yentür, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Halil Yıldız, (Kardiyoloji Anabilim Dalı, Sağlık Bilim Üniversitesi, Gazi Yaşargil Eğitimi ve Araştırma Hastanesi, Diyarbakır, Türkiye)

Lokman Argun, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Kamran İldırımlı, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Bünyamin Yıldırım, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Muhammed Demir, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Mehmet Özbek, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Faruk Ertaş, (Kardiyoloji Anabilim Dalı, Dicle Üniversite Tıp Fakültesi, Diyarbakır, Türkiye)

Diğer Yazarlar

The Anatolian Journal of Cardiology

10 3

Yıl: 2022 Cilt: 26 Sayı: 7 Sayfa Aralığı: 567 - 576 Metin Dili: İngilizce İndeks Tarihi: 09-08-2022

Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study

Öz:

Background: The aim of this study was to investigate the frequency of oral anticoagulant drugs and time in therapeutic range in patients receiving warfarin in addition to the epi- demiological trial of non-valvular atrial fibrillation previously conducted in Turkey (The Atrial Fibrillation: Epidemiological Registry trial). Furthermore, the prevalence of major adverse events and mortality rates of the patients were evaluated during the long-term follow-up period. Methods: We created a national data registry for non-valvular atrial fibrillation patients, reflecting all geographic regions by population density. In that context, the study included all consecutive atrial fibrillation patients older than 18 years of age who were admitted to the cardiology outpatient clinic except for patients those with prosthetic heart valves and rheumatic mitral valve stenosis. Results: This study included 2592 patients from 35 different centers. The mean age was 68.7 ± 11.1 years, and 55.5% of the patients were female. The most common comorbid diseases were chronic kidney disease (69%) and hypertension (65.5%). The time in ther- apeutic range rate in the general population was 40%, and the mortality rate at 5-year follow-up was 29.4%. Conclusion: The Atrial Fibrillation: Epidemiological Registry 2 study showed higher use of anticoagulant in non-valvular atrial fibrillation patients than in previous national stud- ies. Furthermore, this study demonstrated that most of the non-valvular atrial fibrilla- tion patients are in the high-risk group and the time in therapeutic range rates are still low in Turkey. As a result, this is a significant reason for switching from warfarin to non-K vitamin-dependent new oral anticoagulant treatments.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Tho- racic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42:373-498.
2. Uyarel H, Onat A, Yüksel H, Can G, Ordu S, Dursunoğlu D. Inci- dence, prevalence, and mortality estimates for chronic atrial fibrillation in Turkish adults. Turk Kardiyol Dern Ars. 2008;36(4):214-222.
3. Sayın B, Okutucu S, Yılmaz MB, et al. Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in TURKEY: inferences from GARFIELD-AF registry. Anatol J Cardiol. 2019;21(5):272-280. [CrossRef]
4. Ertas F, Eren NK, Kaya H, et al. The atrial fibrillation in Turkey: epidemiologic Registry (AFTER). Cardiol J. 2013;20(4):447-452. [CrossRef]
5. Diker E, Bellur G, Yıldız N, İzgi C, Naditch-Brûlé L. Evaluation of atrial fibrillation (AF) management and cardiovascular risk pro- file in AF patients: data from Turkish patients in the interna- tional observational cross-sectional REALISE AF trial. Turk Kardiyol Dern Ars. 2015;43(1):60-74. [CrossRef]
6. Ertaş F, Kaya H, Yıldız A, et al. An epidemiological study to eval- uate the use of vitamin K antagonists and new oral anticoagu- lants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design. Turk Kardiyol Dern Ars. 2015;43(2):169- 177. [CrossRef]
7. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagu- lant therapy. Thromb Haemost. 1993;69(3):236-239. [CrossRef]
8. Schulman S, Kearon C, Subcommittee on Control of Anticoagu- lation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Defini- tion of major bleeding in clinical investigations of antihemo- static medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. [CrossRef]
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refi ning clini- cal risk stratifi cation for predicting stroke and thromboembo- lism in atrial fi brillation using a novel risk factor-based approach: the euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272. [CrossRef]
10. Boriani G, Laroche C, Diemberger I, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128(5):509- 18.e2. [CrossRef]
11. Başaran Ö, Beton O, Doğan V, et al. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatol J Cardiol. 2016;16(10):734- 741. [CrossRef]
12. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combi- nation drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611-614. [CrossRef]
13. Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau- Leclaire J, Duh MS. Impact of daily dosing frequency on adher- ence to chronic medications among nonvalvular atrial fibrilla- tion patients. Adv Ther. 2012;29(8):675-690. [CrossRef]
14. McHorney CA, Crivera C, Laliberté F, et al. Adherence to nonvi tamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin. 2015;31(12):2167-2173. [CrossRef]
15. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Con- nors S. Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol. 2016;32(6):747-753. [CrossRef]
16. Emren SV, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antag- onist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018;24(3):525-531. [CrossRef]
17. Basaran O, Filiz Basaran N, Cekic EG, et al. PRescriptiOn Pat- tERns of Oral anticoagulants in nonvalvular atrial fibrillation (PROPER study). Clin Appl Thromb Hemost. 2017;23(4):384-391. [CrossRef]
18. Turk UO, Tuncer E, Alioğlu E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observa- tional, prospective water Registry. Cardiol J. 2015;22(5):567-575. [CrossRef]
19. Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitaliza- tion for patients with atrial fibrillation: results from the Out- comes Registry for Better Informed Treatment of Atrial Fibrilla- tion (ORBIT-AF). Am Heart J. 2014;167(5):735-42.e2. [CrossRef]
20. Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the inter- national, observational, prospective GARFIELD registry. PLOS ONE. 2013;8(5):e63479. [CrossRef]
21. Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvu- lar atrial fibrillation: the Gloria-AF registry, Phase II. Am J Med. 2015;128(12):1306-13.e1. [CrossRef]
22. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an antico- agulated atrial fibrillation cohort. Stroke. 2010;41(12):2731- 2738. [CrossRef]

APA	GÜZEL T, Aktan A, Kılıç R, Arslan B, ARIK B, Yentür M, YILDIZ H, Argun L, İldırımlı K, Yıldırım B, DEMİR M, özbek m, ERTAŞ F (2022). Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. , 567 - 576.
Chicago	GÜZEL Tuncay,Aktan Adem,Kılıç Raif,Arslan Bayram,ARIK BARAN,Yentür Merve,YILDIZ Halil,Argun Lokman,İldırımlı Kamran,Yıldırım Bünyamin,DEMİR Muhammed,özbek mehmet,ERTAŞ Faruk Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. (2022): 567 - 576.
MLA	GÜZEL Tuncay,Aktan Adem,Kılıç Raif,Arslan Bayram,ARIK BARAN,Yentür Merve,YILDIZ Halil,Argun Lokman,İldırımlı Kamran,Yıldırım Bünyamin,DEMİR Muhammed,özbek mehmet,ERTAŞ Faruk Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. , 2022, ss.567 - 576.
AMA	GÜZEL T,Aktan A,Kılıç R,Arslan B,ARIK B,Yentür M,YILDIZ H,Argun L,İldırımlı K,Yıldırım B,DEMİR M,özbek m,ERTAŞ F Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. . 2022; 567 - 576.
Vancouver	GÜZEL T,Aktan A,Kılıç R,Arslan B,ARIK B,Yentür M,YILDIZ H,Argun L,İldırımlı K,Yıldırım B,DEMİR M,özbek m,ERTAŞ F Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. . 2022; 567 - 576.
IEEE	GÜZEL T,Aktan A,Kılıç R,Arslan B,ARIK B,Yentür M,YILDIZ H,Argun L,İldırımlı K,Yıldırım B,DEMİR M,özbek m,ERTAŞ F "Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study." , ss.567 - 576, 2022.
ISNAD	GÜZEL, Tuncay vd. "Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study". (2022), 567-576.

APA	GÜZEL T, Aktan A, Kılıç R, Arslan B, ARIK B, Yentür M, YILDIZ H, Argun L, İldırımlı K, Yıldırım B, DEMİR M, özbek m, ERTAŞ F (2022). Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. The Anatolian Journal of Cardiology, 26(7), 567 - 576.
Chicago	GÜZEL Tuncay,Aktan Adem,Kılıç Raif,Arslan Bayram,ARIK BARAN,Yentür Merve,YILDIZ Halil,Argun Lokman,İldırımlı Kamran,Yıldırım Bünyamin,DEMİR Muhammed,özbek mehmet,ERTAŞ Faruk Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. The Anatolian Journal of Cardiology 26, no.7 (2022): 567 - 576.
MLA	GÜZEL Tuncay,Aktan Adem,Kılıç Raif,Arslan Bayram,ARIK BARAN,Yentür Merve,YILDIZ Halil,Argun Lokman,İldırımlı Kamran,Yıldırım Bünyamin,DEMİR Muhammed,özbek mehmet,ERTAŞ Faruk Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. The Anatolian Journal of Cardiology, vol.26, no.7, 2022, ss.567 - 576.
AMA	GÜZEL T,Aktan A,Kılıç R,Arslan B,ARIK B,Yentür M,YILDIZ H,Argun L,İldırımlı K,Yıldırım B,DEMİR M,özbek m,ERTAŞ F Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. The Anatolian Journal of Cardiology. 2022; 26(7): 567 - 576.
Vancouver	GÜZEL T,Aktan A,Kılıç R,Arslan B,ARIK B,Yentür M,YILDIZ H,Argun L,İldırımlı K,Yıldırım B,DEMİR M,özbek m,ERTAŞ F Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. The Anatolian Journal of Cardiology. 2022; 26(7): 567 - 576.
IEEE	GÜZEL T,Aktan A,Kılıç R,Arslan B,ARIK B,Yentür M,YILDIZ H,Argun L,İldırımlı K,Yıldırım B,DEMİR M,özbek m,ERTAŞ F "Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study." The Anatolian Journal of Cardiology, 26, ss.567 - 576, 2022.
ISNAD	GÜZEL, Tuncay vd. "Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study". The Anatolian Journal of Cardiology 26/7 (2022), 567-576.